Neumora Therapeutics
Logotype for Neumora Therapeutics Inc

Neumora Therapeutics (NMRA) investor relations material

Neumora Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Neumora Therapeutics Inc
Q3 2026 earnings summary16 Nov, 2026

Executive summary

  • Clinical-stage pipeline includes NMRA-511 for agitation associated with Alzheimer’s dementia, NMRA-898 for schizophrenia and NMRA-215 for obesity and cardiometabolic disease; no product sales revenue to date.

  • Navacaprant development for MDD was discontinued after KOASTAL-2 and -3 missed primary and key secondary endpoints; a ~35% workforce reduction followed in June 2026.

  • NMRA-215 IND was submitted to the FDA; additional NMRA-511 dose-escalation data were reported.

Financial highlights

  • Q3 2026 net loss was $34.4M, or $0.18/share, versus $56.8M, or $0.35/share, in Q3 2025; 9M net loss was $131.0M versus $177.5M.

  • Q3 operating expenses were $33.4M versus $57.7M; 9M operating expenses were $128.5M versus $182.7M, including $5.0M of acquired in-process R&D in each 2025 nine-month period.

  • Q3 R&D expense was $22.6M versus $40.5M, and G&A expense was $10.8M versus $12.2M; lower clinical trial and personnel costs drove the declines.

  • Cash and cash equivalents were $85.7M at September 30, 2026; accumulated deficit reached $1,315.1M.

  • 9M operating cash use was $119.4M versus $158.5M; financing provided $22.5M, mainly from ATM stock sales.

Outlook and guidance

  • Available cash is not expected to fund operating plans for at least 12 months from issuance of the financial statements; substantial doubt about continuing as a going concern was concluded.

  • Significant losses and negative operating cash flows are expected to continue as clinical and preclinical programs advance; product revenue is not expected for years, if ever.

  • Additional funding is required to continue operations and develop product candidates; expected sources include equity or debt financing, collaborations or other capital, with no assurance of availability or acceptable terms.

  • Management cited disciplined capital allocation toward programs with the greatest potential value and evaluation of financing options to fund lead programs through upcoming value inflection points.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Neumora Therapeutics earnings date

Logotype for Neumora Therapeutics Inc
Q4 202619 Mar, 2027
Neumora Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Neumora Therapeutics earnings date

Logotype for Neumora Therapeutics Inc
Q4 202619 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Neumora Therapeutics Inc., known as NMRA, is a clinical-stage biopharmaceutical company focused on the development of therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Founded in 2019 and formerly known as RBNC Therapeutics, Inc., Neumora aims to redefine neuroscience drug development by integrating data science with neuroscience to pioneer precision medicines for complex brain diseases. The company's pipeline includes various programs at different stages of clinical trials targeting diseases such as major depressive disorder, agitation associated with dementia due to Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Parkinson's disease, among others. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq.